Roche TCRC, Inc.
Records under this name other than patents Roche TCRC, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,760,807 | GPC3-Targeting Drug Which Is Administered To Patient Responsive To GPC3-Targeting Drug Therapy now held by F. Hoffmann-La Roche AG In force · High confidence | In force | High confidence | |
| US 10,265,279 | Combinations of LSD1 Inhibitors for Use in the Treatment of Solid Tumors conveyed to Hoffmann la Roche Inc. - now held by Oryzon Genomics, S.A. In force · High confidence | In force | High confidence | |
| US 12,195,547 | Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate conveyed to Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 12,729,243 | Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody conveyed to Hoffmann-La Roche Inc. In force · Medium confidence | In force | Medium confidence | |
| 15/624,813 | Biomarkers for HBV treatment response conveyed to Hoffmann-La Roche Inc. Abandoned Abandoned Jul 22, 2019 | Abandoned | Abandoned Jul 22, 2019 | |
| 16/752,537 | Combination Therapy with a Bet Inhibitor, a BCL-2 Inhibitor and an ANTI-CD20 Antibody conveyed to Hoffmann-La Roche Inc. Abandoned Abandoned Aug 8, 2022 | Abandoned | Abandoned Aug 8, 2022 | |
| 16/752,570 | Combination Therapy with a Bet Inhibitor and a BCL-2 Inhibitor conveyed to Hoffmann-La Roche Inc. Abandoned Abandoned Oct 13, 2021 | Abandoned | Abandoned Oct 13, 2021 | |
| 17/263,691 | Pharmaceutical Composition for Use in the Treatment or Prevention of a C5-RELATED Disease and a Method for Treating or Preventing a C5-RELATED Disease conveyed to Hoffmann la Roche Inc. - now held by Chugai Seiyaku Kabushiki Kaisha and Osaka University Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/788,487 | Method of Treating Virus Infection Using a TLR7 Agonist conveyed to Hoffmann-La Roche Inc. Abandoned Abandoned Mar 27, 2026 | Abandoned | Abandoned Mar 27, 2026 | |
| 17/795,617 | Method for Determining Accuracy of Heart Rate Variability conveyed to Hoffmann-La Roche Inc. Abandoned Abandoned Nov 10, 2025 | Abandoned | Abandoned Nov 10, 2025 |